title: Predictive value of response to treatment of T-lymphocyte subpopulations in idiopathic pulmonary fibrosis.
abstract: T-cell types are important in maintaining immune homeostasis in the lung and their imbalance may be associated with several diseases. We examined the relationship between bronchoalveolar lavage (BAL) T-cell subset profiles and the clinical course of 46 patients with idiopathic pulmonary fibrosis (IPF). A flow cytometry cell sorter (FACS) was used to analyse the T-cell subsets. Pulmonary function tests (PFT) were performed at baseline and 6-12 months later. Patients were divided into two groups according to their CD4/CD8 ratio: CD4/CD8 >1 (group 1, n=21); and CD4/CD8 <1 (group 2, n=25). A lower percentage of lymphocytes, a higher percentage of CD8/S6F1 cells (cytotoxic T-lymphocytes) and a higher percentage of neutrophils were found in the BAL in group 2 compared to group 1 (11+/-7.5% versus 19+/-13.2%; p=0.024 and 29.8+/-17.6% versus 13.3+/-6.9%; p=0.068, respectively for lymphocytes and cytotoxic T-lymphocytes; and 8+/-11% versus 29+/-27%; p=0.003 for neutrophils). Inversely, in the peripheral blood, the distribution of CD8/S6F1 cells was lower in group 1 than in group 2 (8.3+/-6.9% versus 33.4+/-16.5%; p=0.0048). The patients were followed over a period of 1 yr in order to test whether those findings could determine efficacy of therapy. The baseline transfer factor of the lung for carbon monoxide (TL,CO) capacity in group 1 and group 2 was 59+/-22% and 51+/-21%, respectively (p=0.29), but only in group 1 was the TL,CO capacity improved significantly in response to steroids treatment after 6-12 months. IPF patients with a higher percentage of lymphocytes, a lower percentage of neutrophils, CD4/CD8 >1 and a low percentage of CD8/S6F1 may have a more benign course of disease. These parameters may identify an early stage of reversible disease responsive to therapy. We conclude that these measurements may be a useful tool in monitoring response to treatment in patients with idiopathic pulmonary fibrosis.
authors.affiliation: The Dept of Pulmonary and Allergic Diseases, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
authors.forename: E
authors.initials: E
authors.lastname: Fireman
authors.forename: N
authors.initials: N
authors.lastname: Vardinon
authors.forename: M
authors.initials: M
authors.lastname: Burke
authors.forename: S
authors.initials: S
authors.lastname: Spizer
authors.forename: S
authors.initials: S
authors.lastname: Levin
authors.forename: A
authors.initials: A
authors.lastname: Endler
authors.forename: D
authors.initials: D
authors.lastname: Stav
authors.forename: M
authors.initials: M
authors.lastname: Topilsky
authors.forename: A
authors.initials: A
authors.lastname: Mann
authors.forename: Y
authors.initials: Y
authors.lastname: Schwarz
authors.forename: S
authors.initials: S
authors.lastname: Kivity
authors.forename: J
authors.initials: J
authors.lastname: Greif
mesh_terms: D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D016516:CD4-CD8 Ratio; D002452:Cell Count; D002469:Cell Separation; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D011241:Prednisone / Q000627:therapeutic use*; D011658:Pulmonary Fibrosis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D012129:Respiratory Function Tests; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D013997:Time Factors
chemical_list: D005938:Glucocorticoids; D011241:Prednisone